Shaping the Future of Hormonal Health: Advancing Endocrine & Metabolic Research and TherapieS
At Geistek Pharmaceuticals, we are passionately dedicated to addressing the challenges of endocrine and metabolic disorders to improve the health and well-being of people worldwide. Our commitment lies in driving scientific innovation and developing cutting-edge therapies to treat a wide range of hormonal and metabolic disorders.
Our expertise spans diverse endocrine and metabolic disorders, including diabetes, thyroid disorders, lipid metabolism disorders, metabolic syndrome, adrenal gland disorders, growth disorders, and many others. We recognize the complexity of these disorders and strive to understand their underlying causes while developing innovative and personalized therapies that enhance patients’ quality of life.
At Geistek Pharmaceuticals, we have a multidisciplinary team of scientists, physicians, and research experts, all dedicated to finding effective solutions for endocrine and metabolic disorders. Our approach is rooted in rigorous research, the application of state-of-the-art technologies, and the use of robust scientific data to drive the discovery and development of new therapies.
We work closely with leading medical experts, academic institutions, and regulatory bodies to ensure that our research meets the highest ethical and regulatory standards. Additionally, we strive to stay up-to-date with the latest scientific advancements and innovative clinical practices to provide patients with cutting-edge treatment options.
At Geistek Pharmaceuticals, we understand that each patient is unique and deserves personalized care. We are committed to delivering therapies tailored to the individual needs of each person, leveraging the latest advances in personalized medicine and state-of-the-art technology.
We are firmly dedicated to improving health worldwide and believe in the importance of collaboration and knowledge sharing. We work closely with medical communities, patients, and advocacy groups to drive awareness, education, and access to innovative treatments.
Geistek Pharmaceuticals is here to help individuals struggling with endocrine and metabolic disorders find hope, relief, and an improved quality of life. Together, we will move towards a future where these disorders are understood, treated, and overcome. Welcome to Geistek Pharmaceuticals, where innovation and well-being intersect at the core of our commitment to endocrine and metabolic health.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
